drugset / Trial / NCT00841048

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses

NCT00841048

Phase 1 Completed 107 enrolled AstraZeneca
RandomizedSingle-groupSingle-blind

Summary

The primary aim of this study is to investigate the safety and tolerability of AZD4017 when given as multiple oral ascending doses to healthy volunteers. This will be done by comparing the effect of AZD4017 to placebo. The study will aslo investigate the absorption, distribution and disappearance of AZD4017 in the body. Information about plasma concentrations of AZD4017 vs time after dose intake will also be collected and some measures of pharmacokinetics versus pharmacodynamics will be included. The future indication for AZD4017 is planned to be Type 2 Diabetes Mellitus.

Timeline

Start
2009-02
Primary completion
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4017 Small molecule 75 mg Oral